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Abstract ILl3 induces the same biological effects as IIA in 
normal human B cells. We show that as in the IL4R complex, 
both IIARcz and IL2Ryc are components of the IL13R and that 
both cytokines induced STAT6, STAT3 and STAT5 activation 
in B cells. In spite of this similar downstream signalling, IIA and 
ILl3 used a different set of Janus kinases: ILl3 is unable to 
activate JAK1 and JAK3. 
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1. Introduction 
ILl 3 and IL4 have similar biological effects on monocytes, 
mast cells and B lymphocytes [1-4]. They both act on a par- 
tially shared receptor [5]. A specific murine ILl3 binding sub- 
unit has recently been characterized and is a new member of 
the hematopoietin receptor family. This subunit may be a 
component of the IL4R complex [6]. There is recent evidence 
for the direct participation of the human IL4Rc¢ chain (the 
specific I IA binding subunit) in the IL13R complex [4,7]. The 
long cytoplasmic tail of IL4Rc¢ anchors several molecules es- 
sential for IL4 signalling, including IRS-2/4PS, NF-IL4/ 
STAT6, JAK1 and indirectly JAK3 [8-12]. IL l3 induces the 
activation of different IL4Rcc-associated molecules, such as 
4PS and JAK1 in the human TF-1 cell line [13,14] or 
STAT6 in the murine U937 cell line [15]. However, the details 
of ILl3 signalling remain elusive, especially in human B cells. 
The involvement of the yc chain in IL4 and ILl3 receptor 
complexes i  also unclear. Although many reports have shown 
that ~c is required for IL4 signalling [16-19], recent data sug- 
gest that there is an alternative pathway [20]. Indeed, neither 
X-SCID B lymphocytes [21] nor renal carcinoma cells [22], 
contain a functional ~ chain and IL4 signalling is normal. 
We investigated the yc chain in IL13R and IL4R complexes 
and some of the corresponding transduction mechanisms in 
normal human B cells. As previously reported in other cell 
types [23], B cell stimulation by IL l3 led to the tyrosine phos- 
phorylation of the IL4Re¢ chain. Surprisingly, the IL2R7 
chain was recruited by the IL4Rc¢ chain after both IL4R 
and IL13R triggering. This recruitment was required for 
JAK3 activation in I IA signalling. However, no phosphoryla- 
tion of JAK enzymes was detected in IL l3 signalling. IL13R 
triggering activated various STAT proteins including STAT6, 
STAT5 and STAT3. Thus, the IL13-induced tyrosine phos- 
phorylation of the IL4Rc¢ and the IL13-induced activation of 
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STATs in human B cells appear to be mediated by as yet 
uncharacterized proteins tyrosine kinases. 
2. Materials and methods 
2.1. Reagents and antibodies 
Recombinant human IL4 was purchased from Genzyme (Cam- 
bridge, CA). Recombinant human ILl3 was kindly provided by A. 
Minty (Sanofi, Lab~ge, France). Human recombinant IL2 was pur- 
chased from Biogen (Geneva, Switzerland). Two purified mouse mAbs 
raised against human IL4 Receptor mAb were used: M-57 (IgG1) 
from Immunex Corp. (Seattle, WA) and $4S6C9 (IgG) from Immu- 
notech (Marseille, France). $4S6C9 is only satisfactory in immunpre- 
cipitation experiments. Mouse anti-human phosphotyrosine (4G10) 
and agarose-conjugated anti-phosphotyrosine 4G10 were from Up- 
state Biotechnology Inc. (UBI, Lake Placid, NY). Rabbit JAK3 and 
JAKI antisera were kindly provided by J.J. O'Shea (NCI, Frederick, 
MD) and A. Ziemiecki (University of Berne, Berne, Switzerland), 
respectively. To immunoprecipitate yc chains, we used a rat ~c mAb 
(TUGh4), provided by Dr. K. Sugamura (Tohoku University School 
of Medecine, Sendai, Japan). A commercial rabbit yc Ab from Santa 
Cruz Biotechnology (Tebu, Le Perray en Yvelines, France), was used 
for Western blotting. The mouse T10-2 monoclonal ntibody directed 
against Tyk2 was provided by S. Pellegrini (Institut Pasteur, Paris, 
France). Rabbit STAT6 and STAT3 antibodies were purchased from 
Santa Cruz Biotechnology and mouse anti-STAT5 was from Trans- 
duction Laboratories (Lexington, KY). Anti-mouse and anti-rabbit Ig
horseradish peroxidase-linked whole antibodies were from Amersham 
Corp., UK. 
2.2. B cells 
Human mononuclear cells were obtained from tonsils removed 
from children with chronic tonsillitis. Resting B ceils were isolated 
from the E-fraction by Percoll gradient separation as previously de- 
scribed [24]. The resting B cell suspensions, consistently containing 
->95% CD19+, < 1% CD3+ and <-4% CD14+ cells, were frozen until 
use. After thawing, resting B cells (1 × 106 cells/ml) were stimulated in
complete medium (RPMI 1640 containing 2 mM L-glutamine, 100 Ixg/ 
ml streptomycin, 100 U/ml penicillin, 1mM sodium pyruvate, 10 rnM 
HEPES and 10% heat-inactivated FCS) for 48 h with 1 ~tg/ml phorbol 
12,13 dibutyrate (PDB, Sigma, St Louis, MO and 800 ng/ml ionomy- 
cin (Sigma). Activated B cells were extensively washed before trigger- 
ing by cytokines. 
2.3. Immunoprecipitation 
B cells (1 × 107 cells/ml) were stimulated or not for up to 30 min at 
37°C with IL4 (40 ng/106 cells), ILl3 (200 ng/106 cells) or IL2 (50 ng/ 
l0 s cells). The reaction was stopped by addition of cold PBS contain- 
ing 0.1% azide and 100 IxM Na3V04. After centrifugation, the cells 
were resuspended at 1 × l0 s cells/ml in lysis buffer (50 mM HEPES 
pH 7.5, 0.5% Brij 97, 50 mM NaCI, 50 mM NaF, 10 mM NaPPi, 5 
mM EDTA, 1 mM NazVO4, 1 mM Pefabloc, 10 ~tg/ml aprotinin, 10 
Ixg/ml eupeptin) incubated for 30 min on ice, and centrifuged for 30 
min at 13 000 × g at 4°C. Supernatants (equivalent of 1 × 107cells) were 
incubated overnight at 4°C with 15 txl of packed agarose-conjugated 
4G10 beads (cxPY), 5 ~tg of human IL4R Ab (c¢IL4R), or 3 I.tl of yc 
Ab (ccTc). Immune complexes were then collected on 20 Ixl packed 
protein G beads by 1 h incubation at 4°C. 
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2.4. Western blotting 
Immunoprecipitates were washed three times in cold lysis buffer, 
boiled in Laemmli buffer and resolved by 8% SDS-PAGE. Proteins 
were then electrophoretically transferred to nitrocellulose filters (Hy- 
bond-ECL, Amersham Corp., UK). The filters were blocked for at 
least 3 h in TBS (20 mM Tris-HCl pH 7.6, 137 mM NaCI) containing 
3% skimmed milk and 0.1% Tween 20 (blocking buffer). Proteins were 
probed by overnight incubation at 4°C with different antibodies (as 
indicated in the figure legends). After washing in TBS-0.1% Tween 20, 
blots were incubated in blocking buffer with horseradish peroxidase- 
labelled anti-mouse (1/3000) or anti-rabbit Ig (1/10 00) Ab for 45 min 
at 20°C, washed again and exposed to an enhanced chemilumines- 
cence detection system (ECL, Amersham Corp., UK). ECL detection 
was recorded on ECL Hyperfilms (Amersham). The exposed films 
were scanned on an Imstar densitometer. 
Before reprobing, membranes were stripped in 30 mM 2-mercap- 
toethanol, 2% SDS, 62.5 mM Tris-HCl buffer pH 6.7, for 30 min at 
50°C. 
3. Results 
3.1. ILl3 induces time-dependent tyrosine phosphorylation of 
IL4Rot chain and increases its association with IL2Ryc 
Human B cells were stimulated with ILl3 and ILA for 1-30 
min, and lysates were immunoprecipitated with ctPY-4G10 
Ab and blotted with anti-IL4Rct Abs (Fig. 1). ILl3 strongly 
increased the degree of tyrosine phosphorylation f IL4Rct as 
early as 1 min after cell stimulation. Phosphorylation i - 
creased up to 15 min and plateaued thereafter (Fig. 1A). Un- 
der similar experimental conditions, tyrosine phosphorylation 
of the hlL4Rc~ was not detectable following IL4 stimulation 
(Fig. 1B). M57 mAb detected two bands of 97 and 130 kDa in 
4G10 immunoprecipitates but detected only the upper band in 
$4S6C9 (IL4Rct) immunprecipitates. This suggests that the 97 
kDa band corresponded to a degraded form of the IL4Ra, 
previously observed in M57 immunoprecipitates blotted with 
M57 [24]. 
The kinetics of the association between 7c and IL4Ra after 
ILl3 and IL4 stimulation were next studied to determine 
whether 7c also participated in the IL13R complex. Both 
ILl3 and IL4 induced a 3-fold increase in the amount of 
IL4Rt~ detected in IL2RTc immunoprecipitates after 1 or 5 
min of stimulation. However, the amount decreased thereafter 
(Fig. 2A,B). In anti-IL4R~t immunoprecipitates, thekinetics 
of recruitment of yc were different after IL4 or ILl3 stimula- 
tion: recruitment was maximal between 1and 5 min with IL4 
but increased up to 15 min with ILl3 (Fig. 2C,D). Thus, these 
data suggest that in normal human B cells, both IL4Rc~ and 
7c are involved in ILl3 signalling. 
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Fig. 1. Time course of IL4Rct tyrosine phosphorylation after ILl3 
stimulation. Human B cells were not stimulated or stimulated at 
370C with ILl3 (200 ng/ml) (A) or IL4 (40 ng/ml) (B) for various 
times. 4G10 and IL4R~ (clone S4S6C9) immunoprecipitates were 
blotted with IL4Ra (10 gg/ml) antibody. Molecular mass tandards 
(kDa) are indicated in the right margin. The position of IL4Rcc is 
shown in the left margin (arrow). 
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Fig. 2. Association between IL4Rct and 7c upon ILl3 and IL4 stim- 
ulation. Human B cells were not stimulated or stimulated at 37°C 
with IL4 (40 ng/ml) (A,C) or ILl3 (200 ng/ml) (B,D) for various 
times. 7c and IL4Rct immunoprecipitates w re blotted with IL4Rtx 
(10 ~tg/ml) (A,B) and with ?c (1 ~tg/ml) antibodies (C,D), respec- 
tively. Molecular mass standards (kDa) are indicated in the right 
margin. The position of the IL4Rct or the yc is shown in the left 
margin (arrow). 
3.2. Neither JAK1 nor JAK3 is activated after IL13R 
triggering 
We next investigated whether JAK3 and JAK1 are stimu- 
lated after IL13R triggering. The kinetics of JAK tyrosine 
phosphorylation were studied in activated human B cells after 
stimulation by IL4 or ILl3 (Fig. 3). JAK1 and JAK3 were 
tyrosine phosphorylated after IL4R triggering from 1 to 15 
min, in all experiments performed. In contrast, neither JAK3 
nor JAK1 was activated by IL13R triggering. In 5 of 9 ex- 
periments, both I1A and ILl3 induced the tyrosine phosphor- 
ylation of Tyk2, another member of the JAK family (Fig. 3). 
No tyrosine phosphorylation f JAK2 was observed in B cells 
after IIA or after ILl3 stimulation (data not shown). 
3.3. A similar pattern of STA T proteins is activated by IL4 and 
IL13 in human B cells 
We compared the pattern of signal transducer and activator 
of transcription (STAT) proteins activated by IL4, ILl3 and 
IL2 in human activated B cells. IL4 but not IL2 induced 
strong tyrosine phosphorylation f STAT6 in human B cells. 
STAT6 activation was clearly detected at 5 rain of IL4 stimu- 
lation and remained steady for 30 rain (Fig. 4A). ILl3 in- 
duced STAT6 tyrosine phosphorylation was maximum at 
5 min and decreased slowly thereafter (Fig. 4A). 
In human activated B cells, IL4, like IL2 in activated T cells 
[25,26], induced the tyrosine phosphorylation f STAT5 and 
STAT3 proteins. IL4 induced tyrosine phosphorylation within 
5 min and continued until 30 min for both STAT proteins 
(Fig. 4B,C). STAT5 exhibited a sharp peak of tyrosine phos- 
phorylation 5 min after IL13R triggering. ILl3 also strongly 
induced activated STAT3 at 1 and 5 min, but activation de- 
creased within 15 rain. In all experiments, phosphorylation f 
STAT6, STAT5 and STAT3 proteins was weaker after stimu- 
lation by ILl3 than by IL4 (Fig. 4A-C). 
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4. Discussion 
We compared the structure of IL13R and IL4R, and their 
signalling mechanisms in human B cells. Although one of the 
early events in IL4R signalling is tyrosine phosphorylation f
IL4Rt~ chain, variations of its basal level of phosphorylation 
in human B cells were hardly detectable in IL4Rtx immuno- 
precipitates [24]. We therefore analyzed IIARet phosphoryla- 
tion induced by ILl3 in 4G10 immunoprecipitates. Tyrosine 
phosphorylation of the IL4Rc~ was detectable from 1 to 30 
min following ILl3 stimulation. In contrast, IL4-induced 
IL4Rct phosphorylation remained undetectable after ILAR 
triggering in 4G10 immunoprecipitates. These results, suggest- 
ing the involvement of the IL4Rot in the IL13R as well as in 
the I IAR complex, extend those of Zurawski et al. [4] and 
entirely agree with data from Smertz-Berling and Duschl 
[23] showing ILl  3 induced-IL4Rc~ phosphorylation in the ery- 
throleukemic cell line TF1. The different phosphorylation pat- 
tern of the IL4Rtx chain after I IAR and IL13R triggering 
might indicate that the stochiometry of the IIARet is different 
in each of these receptors. 
Stimulation by ILl3 enhanced the association between 
IL4R(x and IL2Ry in human B cells. This contrasts with pre- 
vious studies uggesting that yc is not essential for the IL13R 
complex [20,22]. Although part of the IL13R complex in hu- 
man B cells, yc did not function in this complex as a docking 
protein for JAK3 as it does in the IL4R [16]: we observed no 
phosphorylation of JAK3 upon ILl3 stimulation. There are 
two possible xplanations: (i) yc makes a greater contribution 
to conformation than for function of the IL13R; (ii) yc as- 
sociates with JAK another than JAK3. Murata et al. [27] 
reported JAK2 activation after IL13R and I IAR triggering 
in human colon carcinoma cells. However, we were unable 
to detect JAK2 phosphorylation i  human B cells (data not 
shown). Thus, in our model, IL l3 did not induce JAK1, 
JAK3 or JAK2 phosphorylation, and activated Tyk2 in only 
half of the experiments, uggesting that an unkown PTK is 
responsible for ILl3 induced-IIARt~ phosphorylation. Lai et 
al. [28] recently identified JAK3 isoforms which differ from 
that of classic JAK3 in their carboxylic parts, although all 
have similar NH2 regions. Thus, they compete with JAK3 
for complexing with the yc chain without being recognized 
by antibodies pecific for the classic JAK3 protein. Possibly, 
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Fig. 3. Activation of JAK kinases by IL4 and ILl3. Human acti- 
vated B ceils were not stimulated or stimulated at 37°C with IL4 
(40 ng/ml) or ILl3 (200 ng/ml) for the indicated times. The 4G10 
immunoprecipitates were blotted with JAK1 (1/500), JAK3 (1/100) 
or Tyk2 (1/3000) antibodies. Each film was scanned on a densito- 
meter. The relative intensities of the bands are shown as a dia- 
gramm and expressed in arbitrary units (peak area). 
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Fig. 4. Activation of the STATs proteins by IL4 and ILl3. Human 
activated B cells were not stimulated or stimulated at 37°C with IL4 
(40 ng/ml), ILl3 (200 ng/ml), or IL2 (50 ng/ml) for the indicated 
times. 4G10 immunoprecipitates were blotted with STAT6 (1/100) 
(A), STAT5 (1/200) (B) STAT3 (1/100) (C) antibodies. 
Tc/JAK3 isoform complexes are involved in ILl3 signalling in 
normal human B cells. 
STAT6 was activated upon ILl3 stimulation. This is con- 
sistent with the data of Izuhara et al. [29] showing that ILl3, 
but not IL4, activates STAT6 in EBV-transformed B cells of 
XSCID patients. These results suggest that STAT6 activation 
requires, in addition to IIARct working as a STAT6 anchor 
chain, the expression of complex including a ~'c chain and an 
unidentified JAK. The human equivalent of the mouse ILl3 
binding chain [6] (also called the IL13R~x chain) seems a good 
candidate for ~'c. We also detected the phosphorylation of
STAT3 and STAT5 after IL4R and IL13R triggering. As 
for STAT6, the maximum level of phosphorylation of STAT 
3 and 5 induced by ILl3 was weaker than that induced by 
IL4. The activation of these STATs was steady for 30 min 
during 11_.4 stimulation, but decreased quickly (within 15 min) 
upon ILl3 stimulation. As previously reported by two groups 
[25,26], IL4, IL2 and ILl5 all induce STAT3 tyrosine phos- 
phorylation in T cells, suggesting that its activation depends 
on Tc expression. In contrast, STAT5 activation induced by 
IL4 and ILl3, detected in B cells, might be associated with 
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IL13Rtx chain expression. The nature of the biological effects 
of these STAT and the mechanism by which they are acti- 
vated, since there are no specific anchors for STAT3 and 
STAT5 on IL4Rct chain, are unknown. In view of a recent 
report that STAT3 associates with c-jun, it seems likely that 
there are various mechanisms for activating STAT proteins 
[30]. 
In conclusion, we have shown that ~ is recruited by IL4R~ 
after either IL4 or ILl3 stimulation. Although ILl3 induces 
tyrosine phosphorylation of IL4Rc~ and of STAT6 in human 
B cells, it does not activate classic JAKs. We conclude there- 
fore that unlike the IL4R complex, IL13R includes three 
chains: IL13Rc~, IL4Rct and Tc in normal human B cells. 
However, in B cells from XSC1D patients, IL4 and ILl3 act 
in the absence of a functional Tc chain [21,29]. This suggests 
that the Tc (normal B cells) or a T'c (X-SCID B cells and 
carcinoma cells) are used in the IL13R complex. Thus, 
IL4R and IL13R appear to be highly flexible receptors with 
different structures in different cell types and using different 
sets of PTKs. In addition to STAT6, they are also able to 
activate STAT5 and STAT3 proteins in B cells. 
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